Our data suggest that more CML patients with secondary BCR::ABL1-negative MPN are diagnosed when testing for the JAK2, CALR, and MPL mutation is prompted by emerging changes in the blood count. This evidence concerns the gene ABL1 and myeloproliferative neoplasm.